215 related articles for article (PubMed ID: 18855659)
1. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chantratita W
Curr HIV Res; 2008 Sep; 6(5):474-6. PubMed ID: 18855659
[TBL] [Abstract][Full Text] [Related]
2. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
Córdova E; Loiza E; Porteiro N; Mingrone H
Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625
[TBL] [Abstract][Full Text] [Related]
3. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
Taiwo B; Chaplin B; Penugonda S; Meloni S; Akanmu S; Gashau W; Idoko J; Adewole I; Murphy R; Kanki P
Curr HIV Res; 2010 Apr; 8(3):194-8. PubMed ID: 20163340
[TBL] [Abstract][Full Text] [Related]
6. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Reuman EC; Rhee SY; Holmes SP; Shafer RW
J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
[TBL] [Abstract][Full Text] [Related]
7. Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Tambuyzer L; Thys K; Hoogstoel A; Nijs S; Tomaka F; Opsomer M; De Meyer S; Vingerhoets J
Antivir Ther; 2016; 21(4):317-27. PubMed ID: 26566161
[TBL] [Abstract][Full Text] [Related]
8. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
[TBL] [Abstract][Full Text] [Related]
10. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
11. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
Kiertiburanakul S; Wiboonchutikul S; Sukasem C; Chantratita W; Sungkanuparph S
J Clin Virol; 2010 Apr; 47(4):330-4. PubMed ID: 20188624
[TBL] [Abstract][Full Text] [Related]
12. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
13. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
16. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
17. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
